(E)-4-(2,4-dimethylphenyl)but-3-en-2-one | 70233-10-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-4-(2,4-dimethylphenyl)but-3-en-2-one
• 英文别名: 4t-(2,4-dimethyl-phenyl)-but-3-en-2-one；4-(2,4-dimethyl-phenyl)-but-3-en-2-one；4t-(2,4-Dimethyl-phenyl)-but-3-en-2-on；2³-Oxo-1.5-dimethyl-2-butenyl-benzol；γ-Oxo-α-(2.4-dimethyl-phenyl)-α-butylen；(E)-4-(2,4-dimethylphenyl)-3-butene-2-one；4-(2,4-Dimethyl-phenyl)-but-3-en-2-on；2.4-Dimethyl-benzalaceton；4-(2,4-Dimethylphenyl)but-3-en-2-one
• CAS: 70233-10-2
• 化学式: C₁₂H₁₄O
• 分子量: 174.243
• InChiKey: CDMRZWHEBWVEOH-FNORWQNLSA-N

物化性质

• 沸点：
  292.7±9.0 °C(Predicted)
• 密度：
  0.986±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (E)-4-(2,4-dimethylphenyl)but-3-en-2-one 在 dirhodium tetraacetate 、 对甲苯磺酰叠氮 、 sodium ethanolate 、 potassium carbonate 作用下， 以 乙醇 、 甲苯 、 乙腈 为溶剂， 反应 22.5h， 生成 ADX71743
  参考文献：
  名称：

  Phasic and Tonic mGlu7 Receptor Activity Modulates the Thalamocortical Network

  摘要：

  Mutation of the metabotropic glutamate receptor type 7 (mGlu7) induces absence -like epileptic seizures, but its precise role in the somatosensory thalamocortical network remains unknown. By combining electrophysiological recordings, optogenetics, and pharmacology, we dissected the contribution of the mGlu7 receptor at mouse thalamic synapses. We found that mGlu7 is functionally expressed at both glutamatergic and GABAergic synapses, where it can inhibit neurotransmission and regulate short-term plasticity. These effects depend on the PDZ-ligand of the receptor, as they are lost in mutant mice. Interestingly, the very low affinity of mGlu7 receptors for glutamate raises the question of how it can be activated, namely at GABAergic synapses and in basal conditions. Inactivation of the receptor activity with the mGlu7 negative allosteric modulator (NAM), ADX71743, enhances thalamic synaptic transmission. In vivo administration of the NAM induces a lethargic state with spindle and/or spike and -wave discharges accompanied by a behavioral arrest typical of absence epileptic seizures. This provides evidence for mGlu7 receptor -mediated tonic modulation of a physiological function in vivo preventing synchronous and potentially pathological oscillations.

  DOI：

  10.3389/fncir.2016.00031
• 作为产物：
  描述：

  间二甲苯 在 盐酸 、 sodium hydroxide 、 三氯化铝 、 copper(l) chloride 作用下， 生成 (E)-4-(2,4-dimethylphenyl)but-3-en-2-one
  参考文献：
  名称：

  Gattermann, Justus Liebigs Annalen der Chemie, 1906, vol. 347, p. 353

  摘要：

  DOI：

文献信息

• 4-(β-Arylvinyl)-3-(β-arylvinylketo)-1-ethyl-4-piperidinols and Related Compounds:  A Novel Class of Cytotoxic and Anticancer Agents
  作者：Jonathan R. Dimmock、Sarvesh C. Vashishtha、J. Wilson Quail、Uma Pugazhenthi、Zbigniew Zimpel、Athena M. Sudom、Theresa M. Allen、Grace Y. Kao、Jan Balzarini、Erik De Clercq

  DOI：10.1021/jm9801455

  日期：1998.10.1

  tumors. In general, Mannich bases containing olefinic bonds were more cytotoxic than the analogues without this functional group, while the piperidines 9 and 11 were more potent than the acyclic analogues 1 and 4, respectively. Correlations were noted between various physicochemical constants in the aryl rings and cytotoxicity. Compound 9d displayed promising in vivo activity against colon cancers. This

  完成了一系列1-芳基-5-二乙基氨基-1-戊-3-酮盐酸盐1和1-芳基-3-二乙基氨基-1-丙烷盐酸盐4的合成。尝试制备相应的双（5-芳基-3-氧代-4-戊烯基）乙胺盐酸盐2和双（3-芳基-3-氧代丙基）乙胺盐酸盐5导致形成一系列4-（β-芳基乙烯基） ）-3-（β-芳基乙烯基酮）-1-乙基-4-哌啶醇盐酸盐9和4-芳基-3-芳基酮-1-乙基-4-哌啶醇盐酸盐11盐10和12。这些化合物的结构通过1 H NMR光谱确定，并通过代表性分子的X射线晶体学证实。大多数化合物对鼠P388和L1210细胞以及人类肿瘤均表现出明显的细胞毒性。通常，含有烯键的曼尼希碱比没有该官能团的类似物具有更高的细胞毒性，而哌啶9和11分别比无环类似物1和4更有效。注意到芳基环中各种物理化学常数与细胞毒性之间的相关性。化合物9d显示出抗结肠癌的有希望的体内活性。这项研究表明，哌啶9和11构成了新型的细胞毒剂。化合物9
• CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS
  申请人：ZHAO R. Yongxin

  公开号：US20170157262A1

  公开（公告）日：2017-06-08

  A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (I), wherein T, L, m, n, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 12 , and R 13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.

  一种具有公式（I）的细胞表面受体结合分子的强效细胞毒药物的共轭物，其中T、L、m、n、Y、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R12和R13在此定义，可用于靶向治疗癌症、自身免疫疾病和传染病。
• Conjugates of Cell Binding Molecules with Cytotoxic Agents
  申请人：Zhao R. Yongxin

  公开号：US20170296663A1

  公开（公告）日：2017-10-19

  A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a Formula (I), wherein T, L, m, n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.

  一种有效的细胞毒性药物的共轭物，带有具有化学式（I）的细胞表面受体结合分子，其中T、L、m、n、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12和R13在此有定义，可用于靶向治疗癌症、自身免疫疾病和传染性疾病。
• Bicyclic nitrogenous fused-ring compound
  申请人：——

  公开号：US20040082781A1

  公开（公告）日：2004-04-29

  The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula or a salt thereof. 1 Wherein R 1 denotes a hydrogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group and the like; R 2 denotes a halogen atom, a cyano group, a nitro group, a C 1-10 alkyl group, a C 2-10 alkenyl group, C 2-10 alkynyl group and the like; R 3 denotes a C 6-14 aromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group, each of which may have a substituent; and X, Y and X are independent of each other and each denotes N or CR 4 (wherein R 4 denotes a hydrogen atom, a halogen atom, a cyano group, a nitro group, an optionally halogenated C 1-6 alkyl group and the like) and, in this case, at least two of X, Y and Z denote CR 4 .

  本发明提供了一种具有优异的促肾上腺皮质激素释放因子受体拮抗活性的新型化合物。即，提供了以下式子或其盐所代表的化合物。其中，R1表示氢原子、C1-6烷基、C1-6烷氧基等；R2表示卤原子、氰基、硝基、C1-10烷基、C2-10烯基、C2-10炔基等；R3表示C6-14芳香族环烃基或5-至14-成员芳香族杂环基，每个基团都可以有取代基；而X、Y和Z互相独立，每个基团表示N或CR4（其中R4表示氢原子、卤原子、氰基、硝基、可选卤代C1-6烷基等），在这种情况下，至少两个X、Y和Z表示CR4。
• IMIDAZO[1,2-b]PYRIDAZINE COMPOUND
  申请人：HIBI Shigeki

  公开号：US20060211696A1

  公开（公告）日：2006-09-21

  The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula or a salt thereof. Wherein R 1 denotes a hydrogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group and the like; R 2 denotes a halogen atom, a cyano group, a nitro group, a C 1-10 alkyl group, a C 2-10 alkenyl group, C 2-10 alkynyl group and the like; R 3 denotes a C 6-14 aromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group, each of which may have a substituent; and X, Y and X are independent of each other and each denotes N or CR 4 (wherein R 4 denotes a hydrogen atom, a halogen atom, a cyano group, a nitro group, an optionally halogenated C 1-6 alkyl group and the like) and, in this case, at least two of X, Y and Z denote CR 4 .

  本发明提供了一种具有出色的促肾上腺皮质激素释放因子受体拮抗活性的新化合物。即，提供一种由以下公式表示的化合物或其盐。其中，R1表示氢原子、C1-6烷基、C1-6烷氧基等；R2表示卤原子、氰基、硝基、C1-10烷基、C2-10烯基、C2-10炔基等；R3表示C6-14芳香族环烃基或5-至14-成员芳香族杂环基，每个基团均可具有取代基；而X、Y和X彼此独立，且每个基团表示N或CR4（其中R4表示氢原子、卤原子、氰基、硝基、可选卤代C1-6烷基等），在这种情况下，至少有两个X、Y和Z表示CR4。